RS54903B1 - Inhibitor fosfoinozitid 3 kinaze sa delom koji vezuje cink - Google Patents

Inhibitor fosfoinozitid 3 kinaze sa delom koji vezuje cink

Info

Publication number
RS54903B1
RS54903B1 RS20160457A RSP20160457A RS54903B1 RS 54903 B1 RS54903 B1 RS 54903B1 RS 20160457 A RS20160457 A RS 20160457A RS P20160457 A RSP20160457 A RS P20160457A RS 54903 B1 RS54903 B1 RS 54903B1
Authority
RS
Serbia
Prior art keywords
compound
cancer
tumor
disease
compounds
Prior art date
Application number
RS20160457A
Other languages
English (en)
Serbian (sr)
Inventor
Xiong Cai
Haixiao Zhai
Chengjung Lai
Changgeng Qian
Rudi Bao
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc filed Critical Curis Inc
Publication of RS54903B1 publication Critical patent/RS54903B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RS20160457A 2011-04-01 2012-03-30 Inhibitor fosfoinozitid 3 kinaze sa delom koji vezuje cink RS54903B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161470849P 2011-04-01 2011-04-01
US201161559489P 2011-11-14 2011-11-14
EP12764605.7A EP2694075B1 (en) 2011-04-01 2012-03-30 Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
PCT/US2012/031361 WO2012135571A1 (en) 2011-04-01 2012-03-30 Phosphoinositide 3-kinase inhibitor with a zinc binding moiety

Publications (1)

Publication Number Publication Date
RS54903B1 true RS54903B1 (sr) 2016-10-31

Family

ID=46931927

Family Applications (2)

Application Number Title Priority Date Filing Date
RS20160457A RS54903B1 (sr) 2011-04-01 2012-03-30 Inhibitor fosfoinozitid 3 kinaze sa delom koji vezuje cink
RSP20190842 RS59219B1 (sr) 2011-04-01 2012-03-30 Inhibitor fosfoinozitid 3 kinaze sa delom koji vezuje cink

Family Applications After (1)

Application Number Title Priority Date Filing Date
RSP20190842 RS59219B1 (sr) 2011-04-01 2012-03-30 Inhibitor fosfoinozitid 3 kinaze sa delom koji vezuje cink

Country Status (29)

Country Link
US (7) US8710219B2 (OSRAM)
EP (2) EP2694075B1 (OSRAM)
JP (3) JP6242331B2 (OSRAM)
KR (2) KR20180108848A (OSRAM)
CN (2) CN103582483B (OSRAM)
AU (1) AU2012236367B2 (OSRAM)
BR (1) BR112013025340B1 (OSRAM)
CA (1) CA2830822C (OSRAM)
CL (1) CL2013002823A1 (OSRAM)
CY (2) CY1117785T1 (OSRAM)
DK (2) DK3111938T3 (OSRAM)
EA (1) EA022434B9 (OSRAM)
ES (2) ES2733128T3 (OSRAM)
HR (2) HRP20160545T1 (OSRAM)
HU (2) HUE028910T2 (OSRAM)
IL (2) IL228588A (OSRAM)
LT (1) LT3111938T (OSRAM)
ME (2) ME03523B (OSRAM)
MX (1) MX340577B (OSRAM)
PE (1) PE20141382A1 (OSRAM)
PL (2) PL2694075T3 (OSRAM)
PT (2) PT2694075T (OSRAM)
RS (2) RS54903B1 (OSRAM)
SG (2) SG10201602569RA (OSRAM)
SI (2) SI2694075T1 (OSRAM)
SM (2) SMT201900435T1 (OSRAM)
TW (1) TWI571469B (OSRAM)
WO (1) WO2012135571A1 (OSRAM)
ZA (2) ZA201307082B (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2749228C (en) * 2009-01-08 2016-05-17 Curis, Inc. Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
SI2694075T1 (sl) * 2011-04-01 2016-07-29 Curis, Inc. Fosfoinozitid 3-kinazni inhibitor z delom, ki veže cink
EP3045453A1 (en) 2011-11-14 2016-07-20 Cephalon, Inc. Uracil derivatives as axl and c-met kinase inhibitors
CN104725301A (zh) * 2013-12-20 2015-06-24 北京蓝贝望生物医药科技股份有限公司 一种1,2-二氢吡啶-2-酮衍生物的制备方法
WO2016169417A1 (zh) * 2015-04-21 2016-10-27 成都金瑞长青生物科技有限公司 嘌呤基-n-羟基嘧啶甲酰胺衍生物及其制备方法和用途
CN109476710B (zh) * 2016-07-19 2021-11-23 国立植物基因组研究所 抗真菌病原体的新蛋白质
MX2019004842A (es) * 2016-11-02 2019-06-20 Curis Inc Terapia de combinación con un inhibidor fosfoinositida 3-cinasa con un resto de unión a cinc.
CA3081815A1 (en) * 2017-11-06 2019-05-09 Cold Spring Harbor Laboratory Method and compositions for forming a copper-containing complex and uses thereof
BR112021004371A2 (pt) * 2018-09-11 2021-05-25 Curis Inc. terapia em combinação com um inibidor de fosfoinositídeo 3-quinase com uma porção de ligação a zinco
EP3968215A1 (en) 2020-09-09 2022-03-16 Koninklijke Philips N.V. Determining target object type and position
WO2023212574A1 (en) * 2022-04-26 2023-11-02 Olivia Szu Hsieh Lee Nakaya Compositions and methods for modulating rhythmic activity of pacemaker cardiomyocytes

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4828991A (en) 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5502187A (en) 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
US5508269A (en) 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US6083922A (en) 1996-04-02 2000-07-04 Pathogenesis, Corp. Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis
US5767068A (en) 1997-02-13 1998-06-16 Pathogenesis Corporation Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections
KR100774855B1 (ko) 2000-04-27 2007-11-08 아스텔라스세이야쿠 가부시키가이샤 축합 헤테로아릴 유도체
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
ES2306858T3 (es) 2002-03-13 2008-11-16 Janssen Pharmaceutica Nv Derivados de carbonilamino como nuevos inhibidores de las histonadesacetilasas.
OA12792A (en) 2002-03-13 2006-07-10 Janssen Pharmaceutica Nv Sulfonyl-derivatives as novel inhibitors of histone deacetylase.
ES2347544T3 (es) 2002-03-13 2010-11-02 Janssen Pharmaceutica Nv Inhibidores de histona-desacetilasas.
NZ534771A (en) 2002-03-13 2006-04-28 Janssen Pharmaceutica Nv Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
AU2003255845A1 (en) 2002-08-22 2004-03-11 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
CN101153042A (zh) 2003-01-29 2008-04-02 武田药品工业株式会社 噻吩并嘧啶化合物及其用途
AU2005230682B2 (en) 2004-04-05 2010-10-21 Merck Hdac Research, Llc Histone deacetylase inhibitor prodrugs
US8076338B2 (en) 2004-04-23 2011-12-13 Exelixis, Inc. Kinase modulators and methods of use
JP4862654B2 (ja) 2004-10-08 2012-01-25 アステラス製薬株式会社 芳香環縮合ピリミジン誘導体
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
NZ589276A (en) 2005-02-03 2012-06-29 Topotarget Uk Ltd Combination therapies using hdac inhibitors and erlotinib (tarceva)
WO2006122926A1 (en) 2005-05-18 2006-11-23 Janssen Pharmaceutica N.V. Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase
AU2007206942B2 (en) 2006-01-19 2012-08-23 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
CA2633100C (en) 2006-01-19 2014-12-09 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
DK1981871T3 (da) 2006-01-19 2012-02-13 Janssen Pharmaceutica Nv Heterocyclylalkylderivater som hidtil ukendte inhibitorer af histondeacetylase
KR101402474B1 (ko) * 2006-04-26 2014-06-19 제넨테크, 인크. 포스포이노시티드 3-키나제 억제제 화합물 및 이를 포함하는 약학적 조성물
BRPI0710874A2 (pt) 2006-04-26 2012-02-14 Hoffmann La Roche compostos de tienopirimidina, processos de produção dos referidos compostos, composições farmacêuticas contendo os mesmos, kit, produto, e usos dos compostos
MX2008013584A (es) 2006-04-26 2009-03-23 Genentech Inc Compuestos farmaceuticos.
EP2018366A4 (en) 2006-05-16 2010-08-04 Univ Mcgill HYBRID MOLECULES WITH MIXED VITAMIN D RECEPTOR AGONISM AND HISTONDEACETYLASE RESISTANT PROPERTIES
WO2008033745A2 (en) 2006-09-11 2008-03-20 Curis, Inc. Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety
AU2007296740B2 (en) 2006-09-11 2012-09-27 Curis, Inc. Substituted 2-indolinone as PTK inhibitors containing a zinc binding moiety
EP2061772A4 (en) 2006-09-11 2011-06-29 Curis Inc MULTIFUNCTIONAL SMALL MOLECULES AS PROLIFERATION-ACTIVE ACTIVE SUBSTANCES
AU2007296743B2 (en) 2006-09-11 2012-02-16 Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety
US8604044B2 (en) 2006-09-11 2013-12-10 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
CN105481788A (zh) 2006-10-28 2016-04-13 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
ES2571028T3 (es) 2006-12-07 2016-05-23 Genentech Inc Compuestos inhibidores de fosfoinositida 3-cinasa y métodos de uso
AR064155A1 (es) 2006-12-07 2009-03-18 Piramed Ltd Compuestos de inhibidores de fosfoinositido-3 quinasa y metodos de uso
EP2120900A2 (en) 2007-02-15 2009-11-25 Novartis AG Combination of lbh589 with other therapeutic agents for treating cancer
EP2136809A4 (en) 2007-03-20 2012-01-04 Curis Inc INHIBITORS OF RAF KINASE CONTAINING A ZINC BINDING FRAGMENT
WO2009036066A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Vegfr inhibitors containing a zinc binding moiety
TW200922590A (en) 2007-09-10 2009-06-01 Curis Inc VEGFR inhibitors containing a zinc binding moiety
WO2009036057A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Antiproliferative agents containing a zinc binding moiety
TW200922564A (en) 2007-09-10 2009-06-01 Curis Inc CDK inhibitors containing a zinc binding moiety
WO2009036020A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Mek inhibitors containing a zinc binding moiety
EP2205242B1 (en) * 2007-09-12 2015-04-15 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
WO2009042646A1 (en) 2007-09-24 2009-04-02 Curis, Inc. Anti-proliferative agents
JP5348725B2 (ja) 2007-10-25 2013-11-20 ジェネンテック， インコーポレイテッド チエノピリミジン化合物の製造方法
WO2009058895A1 (en) 2007-10-30 2009-05-07 Syndax Pharmaceuticals, Inc. Administration of an inhibitor of hdac and an mtor inhibitor
WO2009086012A1 (en) 2007-12-20 2009-07-09 Curis, Inc. Aurora inhibitors containing a zinc binding moiety
US20110178070A1 (en) 2008-06-24 2011-07-21 Takeda Pharmaceutical Company Limited PI3K/mTOR INHIBITORS
WO2009155659A1 (en) 2008-06-27 2009-12-30 The University Of Queensland Combination therapy
US8196911B2 (en) 2008-10-27 2012-06-12 Honda Motor Co., Ltd. Adjustable rate subframe mount
CA2749228C (en) 2009-01-08 2016-05-17 Curis, Inc. Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
CN102369011A (zh) 2009-03-12 2012-03-07 健泰科生物技术公司 用于治疗造血恶性肿瘤的磷酸肌醇3-激酶抑制剂化合物与化学治疗剂的组合
WO2011054620A1 (en) 2009-10-12 2011-05-12 F. Hoffmann-La Roche Ag Combinations of a pi3k inhibitor and a mek inhibitor
WO2011130628A1 (en) 2010-04-16 2011-10-20 Curis, Inc. Treatment of cancers having k-ras mutations
SI2694075T1 (sl) * 2011-04-01 2016-07-29 Curis, Inc. Fosfoinozitid 3-kinazni inhibitor z delom, ki veže cink
US20130102595A1 (en) 2011-04-15 2013-04-25 Curis, Inc. Treatment of cancers having k-ras mutations
AU2012290121B2 (en) 2011-08-01 2015-11-26 Genentech, Inc. Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors
PT3313443T (pt) 2015-06-25 2023-08-30 Immunomedics Inc Combinação de anticorpos anti-hla-dr ou anti-trop-2 com inibidores de microtúbulos, inibidores de parp, inibidores de bruton quinase ou inibidores de fosfoinositídeo 3-quinase melhora significativamente o resultado terapêutico no cancro
MX2019004842A (es) * 2016-11-02 2019-06-20 Curis Inc Terapia de combinación con un inhibidor fosfoinositida 3-cinasa con un resto de unión a cinc.

Also Published As

Publication number Publication date
US11654136B2 (en) 2023-05-23
US9249156B2 (en) 2016-02-02
TWI571469B (zh) 2017-02-21
US20220168284A1 (en) 2022-06-02
MX340577B (es) 2016-07-13
SI2694075T1 (sl) 2016-07-29
WO2012135571A1 (en) 2012-10-04
IL248597B (en) 2018-04-30
EA022434B1 (ru) 2015-12-30
SMT201900435T1 (it) 2019-09-09
EP3111938B1 (en) 2019-05-08
IL228588A0 (en) 2013-12-31
HRP20191091T1 (hr) 2019-09-20
CY1117785T1 (el) 2017-05-17
SI3111938T1 (sl) 2019-08-30
IL228588A (en) 2016-11-30
EA201301114A1 (ru) 2014-04-30
US20170304279A1 (en) 2017-10-26
LT3111938T (lt) 2019-06-25
SG193563A1 (en) 2013-11-29
AU2012236367A1 (en) 2013-04-18
CN105461736B (zh) 2018-06-12
EA022434B9 (ru) 2016-02-29
JP2018052987A (ja) 2018-04-05
SG10201602569RA (en) 2016-05-30
CY1121825T1 (el) 2020-07-31
ES2733128T3 (es) 2019-11-27
AU2012236367B2 (en) 2014-10-09
ES2577982T3 (es) 2016-07-19
KR20140023333A (ko) 2014-02-26
CN103582483B (zh) 2016-02-17
ME02451B (me) 2016-09-20
DK3111938T3 (da) 2019-07-01
KR20180108848A (ko) 2018-10-04
US20140243330A1 (en) 2014-08-28
PT3111938T (pt) 2019-07-10
CL2013002823A1 (es) 2014-04-11
CA2830822A1 (en) 2012-10-04
ME03523B (me) 2020-04-20
RS59219B1 (sr) 2019-10-31
HK1194969A1 (zh) 2014-10-31
MX2013011132A (es) 2014-03-12
PL2694075T3 (pl) 2016-09-30
ZA201406167B (en) 2015-03-25
PL3111938T3 (pl) 2019-09-30
TW201247678A (en) 2012-12-01
SMT201600179B (it) 2016-08-31
NZ705039A (en) 2016-03-31
EP2694075A1 (en) 2014-02-12
EP2694075A4 (en) 2014-10-01
JP2014509653A (ja) 2014-04-21
US10111864B2 (en) 2018-10-30
CN103582483A (zh) 2014-02-12
US9657032B2 (en) 2017-05-23
HUE028910T2 (en) 2017-01-30
HUE045041T2 (hu) 2019-12-30
US20200215039A1 (en) 2020-07-09
CA2830822C (en) 2018-10-02
HRP20160545T1 (hr) 2016-06-17
EP3111938A1 (en) 2017-01-04
DK2694075T3 (en) 2016-08-01
US8710219B2 (en) 2014-04-29
PE20141382A1 (es) 2014-11-04
BR112013025340A2 (pt) 2016-12-13
JP6242331B2 (ja) 2017-12-06
US10543197B2 (en) 2020-01-28
CN105461736A (zh) 2016-04-06
IL248597A0 (en) 2016-12-29
PT2694075T (pt) 2016-07-11
US20190091211A1 (en) 2019-03-28
ZA201307082B (en) 2015-04-29
BR112013025340B1 (pt) 2021-12-21
US20130090335A1 (en) 2013-04-11
NZ615586A (en) 2015-02-27
JP6275784B2 (ja) 2018-02-07
JP2016188255A (ja) 2016-11-04
US20160185796A1 (en) 2016-06-30
EP2694075B1 (en) 2016-04-27
US11135205B2 (en) 2021-10-05
KR101902325B1 (ko) 2018-09-28

Similar Documents

Publication Publication Date Title
US11654136B2 (en) Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
RS54230B1 (sr) Inhibitori fosfoinozitid 3-kinaze sa delom koji vezuje cink
HK1232775A1 (en) Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
HK1232775B (en) Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
HK1194969B (en) Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
AU2014280913A1 (en) Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
NZ615586B2 (en) Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
NZ705039B2 (en) Phosphoinositide 3-kinase inhibitor with a zinc binding moiety